Checkpoint Therapeutics, Inc. (CKPT): Price and Financial Metrics

Checkpoint Therapeutics, Inc. (CKPT): $4.19

0.14 (+3.33%)

POWR Rating

Component Grades














  • Growth is the dimension where CKPT ranks best; there it ranks ahead of 88.1% of US stocks.
  • CKPT's strongest trending metric is Sentiment; it's been moving up over the last 177 days.
  • CKPT ranks lowest in Momentum; there it ranks in the 4th percentile.

CKPT Stock Summary

  • The ratio of debt to operating expenses for CHECKPOINT THERAPEUTICS INC is higher than it is for about only 0.52% of US stocks.
  • With a price/sales ratio of 364.44, CHECKPOINT THERAPEUTICS INC has a higher such ratio than 98.95% of stocks in our set.
  • Revenue growth over the past 12 months for CHECKPOINT THERAPEUTICS INC comes in at -51.97%, a number that bests merely 3.61% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to CHECKPOINT THERAPEUTICS INC, a group of peers worth examining would be ARAV, FSR, HGEN, IVA, and CNCE.
  • CKPT's SEC filings can be seen here. And to visit CHECKPOINT THERAPEUTICS INC's official web site, go to

CKPT Valuation Summary

  • In comparison to the median Healthcare stock, CKPT's price/sales ratio is 7960% higher, now standing at 403.
  • Over the past 66 months, CKPT's EV/EBIT ratio has gone up 9.4.

Below are key valuation metrics over time for CKPT.

Stock Date P/S P/B P/E EV/EBIT
CKPT 2022-12-02 403.0 -40.4 -0.8 -0.5
CKPT 2022-12-01 388.8 -39.0 -0.7 -0.4
CKPT 2022-11-30 409.7 -41.1 -0.8 -0.5
CKPT 2022-11-29 420.1 -42.2 -0.8 -0.5
CKPT 2022-11-28 451.5 -45.3 -0.8 -0.6
CKPT 2022-11-25 451.5 -45.3 -0.8 -0.6

CKPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CKPT has a Quality Grade of D, ranking ahead of 20.58% of graded US stocks.
  • CKPT's asset turnover comes in at 0.005 -- ranking 410th of 682 Pharmaceutical Products stocks.
  • VBIV, COLL, and ARWR are the stocks whose asset turnover ratios are most correlated with CKPT.

The table below shows CKPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.005 1 4.869
2021-03-31 0.004 1 4.383
2020-12-31 0.033 1 3.944
2020-09-30 0.037 1 3.435
2020-06-30 0.061 1 3.348
2020-03-31 0.117 1 3.498

CKPT Price Target

For more insight on analysts targets of CKPT, see our CKPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.80 Average Broker Recommendation 1.4 (Strong Buy)

CKPT Stock Price Chart Interactive Chart >

Price chart for CKPT

CKPT Price/Volume Stats

Current price $4.19 52-week high $32.71
Prev. close $4.05 52-week low $3.83
Day low $4.06 Volume 97,898
Day high $4.39 Avg. volume 73,539
50-day MA $8.40 Dividend yield N/A
200-day MA $12.19 Market Cap 38.93M

Checkpoint Therapeutics, Inc. (CKPT) Company Bio

Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

CKPT Latest News Stream

Event/Time News Detail
Loading, please wait...

CKPT Latest Social Stream

Loading social stream, please wait...

View Full CKPT Social Stream

Latest CKPT News From Around the Web

Below are the latest news stories about CHECKPOINT THERAPEUTICS INC that investors may wish to consider to help them evaluate CKPT as an investment opportunity.

Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences

WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences. Details are as follows: Cantor Fitzgerald’s Oncology, Hematology & HemeOnc Conference:Date: Wednesday, September 28, 2022Time: 1:45 PM ETFormat: Panel Discussion & 1x1 meetingsPanel: Trends and C

Yahoo | September 22, 2022

H.C. Wainwright Keeps Their Buy Rating on Checkpoint Therapeutics (CKPT)

E ratio of -1.55.

Ryan Adist on TipRanks | August 12, 2022

Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022 Successful completion of pre-BLA meetings in July 2022 Biologics license application (“BLA”) submission for both metastatic and locally advanced cutaneous squamous cell carcinoma on track for later this year WALTHAM, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy

Yahoo | August 12, 2022

We're Keeping An Eye On Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | June 30, 2022

H.C. Wainwright Thinks Checkpoint Therapeutics’ Stock is Going to Recover

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Checkpoint Therapeutics (CKPT – Research Report), with a price target of $26.00. The company's shares closed last Thursday at $1.00, close to its 52-week low of $0.96. According to, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -32.6% and a 17.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Bioline RX Ltd Sponsored ADR, and Lineage Cell Therapeutics.

Catie Powers on TipRanks | June 16, 2022

Read More 'CKPT' Stories Here

CKPT Price Returns

1-mo -38.96%
3-mo -67.27%
6-mo -63.88%
1-year -85.65%
3-year -66.75%
5-year -92.50%
YTD -86.53%
2021 17.36%
2020 54.07%
2019 -5.49%
2018 -53.09%
2017 N/A

Continue Researching CKPT

Here are a few links from around the web to help you further your research on Checkpoint Therapeutics Inc's stock as an investment opportunity:

Checkpoint Therapeutics Inc (CKPT) Stock Price | Nasdaq
Checkpoint Therapeutics Inc (CKPT) Stock Quote, History and News - Yahoo Finance
Checkpoint Therapeutics Inc (CKPT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9164 seconds.